miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1

Meihua Wang¹,*
Qi Wu²,*
Mingming Fang³,*
Wu Huang⁴
Hong Zhu⁵

¹Department of Pathology, Zhongshan Tumor Hospital, Affiliated to Soochow University, Zhongshan, People’s Republic of China; ²Department of Histology and Embryology, Heze Medical College, Heze, People’s Republic of China; ³Department of Radiotherapy, Zhongshan Tumor Hospital, Affiliated to Soochow University, Zhongshan, People’s Republic of China; ⁴Department of Neurosurgery, The Affiliated Changzhou No.2 People’s Hospital of Nanjing Medical University, Changzhou, People’s Republic of China; ⁵Department of Radiation Oncology, Minhang Branch of Cancer Hospital of Fudan University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Introduction

Glioblastoma is recognized as main primary tumor of central nervous system. Even with active treatment including surgery, radiotherapy, and chemotherapy, the survival time after diagnosis is approximately 1–2 years.¹ Brain tumors are a kind of highly invasive and fatal tumor disease,² the incidence is 6–7 new cases per 100,000 person-years.³ Glioblastoma is poorly differentiated astrocytes, which are characterized by high mitotic activity, nuclear atypia, necrosis, cellular polymorphism, vascular proliferation, and thrombosis.⁴

Cisplatin is one of the most widely used cytotoxic drugs (particularly for bladder, ovarian and testicular carcinomas) with the best curative effect for the treatment of a variety of tumors.⁵,⁶ Previous researches have showed that cisplatin is one of the first-line chemotherapeutic drugs adopted for glioblastoma.⁷,⁸ Cisplatin is a DNA damage agent, and its cytotoxic effect is based on the formation of platinum-DNA complex and cross-linking, which leads to cell cycle arrest and...
Despite a certain initial response rate, cisplatin treatment often fails due to the development of resistance to chemotherapy. The development of cisplatin resistance greatly limits its effectiveness in glioblastoma cancer treatment. Therefore, it is of great importance to better understand the mechanism of cisplatin resistance and find an effective combination therapy to combat cisplatin resistance. Multiple studies have shown that microRNAs (miRNAs) are involved in regulation of drug resistance in glioblastoma, which are potential biomarkers and therapeutic targets for patients with glioblastoma.

MicroRNAs (miRNAs) are endogenously expressed short non-coding RNAs of 20–23 nucleotides, which bind to target gene mRNAs’ complementary sequences in the 3′-untranslated regions (UTRs), and involve in regulation of diverse biological processes, including proliferation, differentiation, and apoptosis. MiRNAs’ expression and activity are strictly regulated in time and space, and its aberrant expression is widely associated with the development of human diseases, including cancer. MiRNAs have been reported to play key roles during tumorigenesis and function as oncogenes or tumor suppressors. miR-152 has been proven to be abnormally expressed in several diseases, including cancer, and there is increasing evidences suggesting that miR-152 is a tumor suppressor associated with the proliferation, migration, and invasion of human cancer cells. Recently, Sun et al has collected 30 glioblastoma tissues and adjacent tissues from patients who underwent curative resection, and reported that the expression of miR-152-3p was decreased by more than half in glioblastoma tissues compared with non-tumor samples and normal cells, and overexpression of miR-152-3p induced cell apoptosis and inhibited cell invasion. In this study, we explored the function of miR-152-3p in cisplatin sensitivity of glioblastoma.

Son of sevenless 1 (SOS1) is a dual diguanine nucleotide exchange factor (GEF) for Ras and Rac1, which converts inactive Ras-GDP into active Ras-GTP in many EGF (Epidermal Growth Factor)-stimulated cells. SOS1 is known to participate in EGF-dependent signaling pathways and promote cell survival and growth. Moreover, dysregulation of SOS1 has been found in the progression of numerous cancers including hematological malignancies, breast cancer, skin cancer, and glioblastoma. SOS1 has two Ras binding sites, one of which is an allosteric site distal to the active site, and activation of SOS1 by receptor tyrosine kinase (RTK) would mediate Ras activation. It is widely accepted that Ras plays a critical role in cell growth related signaling pathways. Lv Z and Yang L examined the mRNA and protein expression levels of SOS1 in glioblastoma cell lines and found that the mRNA and protein expression levels of SOS1 were higher than those of the HA cell line. In SOS1 knock-down U87 glioblastoma cells, Ras, p-Raf, and p-ERK were reported to be significantly downregulated, and Lv et al reported that miR-124 was able to suppress the growth of U87 cells by targeting SOS1 through MAPK pathway.

Several studies have reported that miRNAs could regulate cell proliferation or apoptosis by targeting SOS1 in cancer cells. In this research, we aimed to investigate the regulatory association between miR-152-3p and SOS1 as well as their roles in regulation of glioblastoma cisplatin sensitivity. We found that miR-152-3p could increase glioblastoma cisplatin sensitivity via SOS1.

Materials And Methods

Clinical Patient Tissue Samples

A total of 40 tumor tissue samples from patients with glioblastoma and the corresponding 40 non-tumor tissue samples from dead healthy volunteers were collected at Changzhou No.2 People’s Hospital between 2016 and 2018. There were 22 males and 18 females with age ranging from 45 to 74 years, and the average age was 60.3 years. This clinical trial followed the Helsinki Declaration. Written informed consent was acquired from all patients and this study was approved by the Ethics Committee of Changzhou No.2 People’s Hospital. All tissue samples were immediately frozen in liquid nitrogen after surgery and stored in a −80°C refrigerator prior to use.

Cell Culture And Reagent

T98G and U87 human glioblastoma cell lines were purchased from American Type Culture Collection (ATCC, Rockefeller, MD) and cells were cultured in Dulbecco’s modified essential medium (DMEM) (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) and 1% penicillin-streptomycin solution (Life Technologies). Cells were cultured in a 5% CO₂ humidified incubator at 37°C. Cisplatin and
temozolomide (TMZ) were bought from Sigma-Aldrich (St. Louis, MO).

**Overexpression And Inhibition Of miR-152-3p**

MiR-NC inhibitor, miR-152-3p inhibitor, miR-NC mimic, and miR-152-3p mimic were synthesized and purchased from GenePharma (Suzhou, China). Their sequences were as follow: miR-NC inhibitor: 5'-UUCGUGUGUGCGAGGU CGGGAA-3'; miR-152-3p inhibitor: 5'-CAGUAUUCUG UCAUGACUGA-3'; miR-NC mimic: 5'-GGACCCAGU CCACUGUGAAUU-3'; miR-152-3p mimic: 5'-UGCACGU GCAUGACGACUUGG-3'. Approximately 2×10^5 T98G or U87 cells were seeded in each well of 6-well plates. On the next day, 50 nM miR-NC inhibitor or miR-152-3p inhibitor or miR-NC mimic or miR-152-3p mimic was mixed with 10 μL Lipofectamine RNAiMax (Life Technologies) in 250 μL serum-free DMEM for 15 mins. The mixtures were then added into indicated well in 6-well plates. After 48 hrs, the cells were subjected to the following experiments.

**RNA Extraction And Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR) For miRNA And mRNA Assay**

Total RNA was extracted from tissues and cultured T98G and U87 cells using TRIzol reagent (Invitrogen, Carlsbad, CA) and cDNA synthesis was performed using PrimeScript RT reagent kit (TaKaRa, Otsu, Shiga, Japan) according to the manufacturer’s instruction. Real-time RT-qPCR reactions were performed with SYBR Premix Ex Taq (TaKaRa) in a Bio-Rad CFX96 Real-Time PCR System (Bio-rad, Hercules, CA) in triplicate with TB Green™ Fast qPCR Mix (TaKaRa). The reaction conditions were shown as follows: pre-denaturation at 95°C for 30 seconds, denaturation at 95°C for 5 seconds followed by annealing and elongation at 60°C for 10 seconds (repeated for 39 cycles). The relative levels of miR-152-3p and SOS1 were normalized by U6 small nucleolar RNA and GAPDH, respectively. 2^ΔΔCt method was used to calculate gene expression level. The primer sequences were listed as follow: stem loop primer: 5'-CTCAACTGGTGTTCTGCT GGAGTCGCCACATTGAGTTGACAGT-3'; miR-152-3p forward primer: 5'-TCGCCAGGTCTGAGTGAAGAG AA-3'; miR-152-3p reverse primer: 5'-CTCAACTGGTGTT GTGGA-3'; U6 forward primer: 5'-GAGGCGCATTTCC CATGATTT-3'; U6 reverse primer: 5'-TAATTAGAATTAAT TTGACT-3'; SOS1 forward primer: 5'-GAGTGAATCTGT CATGTCGGTT-3'; SOS1 reverse primer: 5'-CTCTCATGTT TGGCCTCTACAC-3'; GAPDH forward primer: 5'-G GAGCCGAGATCCCTCCAAAAT-3'; GAPDH reverse primer: 5'-GGCTGTGTCTACCTTCTCATGG-3'.

**Cell Viability And Apoptosis Assay**

Cell viability assay was performed using Cell Counting Kit-8 kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacture’s instruction. Probably 2×10^6 cells were seeded into each well of 6-well plates. After transfected with 50 nM miR-152-3p mimic or miR-NC mimic, miR-152-3p inhibitor or miR-NC inhibitor, and 2μg pcDNA3-SOS1 or pcDNA3 plasmid for 48 hrs, cells were harvested and seeded in 96-well plate, then treated with different concentrations of cisplatin (2.5, 5, 10, 20, 40 μM) for 48 hrs. 10 μL CCK-8 solution was added into each well, sustained for 2 hrs, and absorbance at 450 nm was measured to reflect cell viability. Annexin-V/Dead Cell Apoptosis Kit (Invitrogen) was used to conduct cell apoptosis assay according to the protocol recommended by the manufacturer’s instruction. Briefly, the cells were harvested and washed in cold phosphate-buffered saline (PBS). Then, the cells were diluted to about 1×10^6 cells/mL in 1XAnnexin-binding buffer to 100 μL per assay. 5 μL Alexa Fluor 488 annexin V and 1 μL 100 μg/mL PI working solution were added to each well of cell suspension. The cells were incubated at room temperature for 15 mins, and then 400 μL annexin-binding buffer was added. Following, we analyzed the stained cells by BD FACS Calibur flow cytometer (BD Biosciences, Franklin Lakes, NJ).

**Western Blot Analysis**

SOS1 antibody (Cat No. PA5-78174, 1:1000) was obtained from Thermo Fisher Scientific (Waltham, MA), GAPDH mouse monoclonal antibody (Cat No. ab8245, 1:10000) was purchased from Abcam (Cambridge, United Kingdom). Anti-mouse (Cat No. CW0221S, 1:10000) secondary antibodies were bought from CWBiotech (Beijing, China). Western blotting was carried out as the following procedure. After collecting cells and washing twice with cold PBS, collected cancer cells were lysed in cold RIPA buffer (Beyotime, Shanghai, China) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), and then incubated on ice for 30 mins. After that, lysates were centrifuged at 12,000×g with 4°C for 15 mins. Protein concentration
was measured by Bicinchoninic Acid Protein Assay kit (BCA, Thermo Fisher Scientific). Equal amounts (20 μg/well) of proteins were separated by 8% SDS-PAGE, transferred to polyvinylidene fluoride (PVDF, millipore, Billerica, MA) membranes, and immunoblotted with the respective antibodies as indicated above, blots were developed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) and the images were obtained by ImageQuant LAS 4000 (GE Healthcare, Little Chalfont, United Kingdom).

Dual-Luciferase Reporter Gene Assay
We used TargetScan (http://www.targetscan.org/) miRNA target prediction database to predict potential target genes of miR-152-3p. We amplified SOS1 3′-UTR region from cDNA of T98G cells and inserted into the pGL3 vector (Promega Corporation, Madison, WI). Two site mutations were introduced to pGL3-SOS1 3′UTR-WT to construct mutant SOS1-3′UTR (SOS1 3′UTR-Mut) with QuikChange Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA). The T98G cells were co-transfected with the 2 μg SOS1 3′UTR-WT or SOS1 3′UTR-Mut plasmid and 50 nM miR-152-3p mimic (or negative control) using Lipofectamine™ 2000 reagent (Invitrogen) for 48 hrs. Luciferase activity was evaluated by using the Dual-Glo Luciferase assay system (Promega Corporation).

Statistical Analysis
In this research, we performed all experiments thrice. GraphPad Prism 5.0 software (San Diego, CA) was used to analyze research data and data were presented as mean ±SD. Student’s t-test was used to analyze differences between two groups. One-way ANOVA was used to compare differences among three or more groups, followed by Newman–Keuls analysis. P<0.05 was considered to indicate a statistically significant difference.

Results
Overexpression Of miR-152-3p Enhanced Cisplatin Sensitivity In Glioblastoma
miR-152-3p has been reported as a tumor suppressor, which is downregulated in many cancer tissues.19,20,29 To explore the role of miR-152-3p in regulation of cisplatin sensitivity of glioblastoma and its underlying mechanisms, we firstly overexpressed miR-152-3p in T98G and U87 glioblastoma cancer cells, respectively, and results showed that miR-152-3p mimic successfully overexpressed miR-152-3p in the two cancer cell lines (Figure 1A). Overexpression of miR-152-3p in T98G and U87 cells did not affect glioblastoma cell viability (Figure 1B). However, overexpressed miR-152-3p significantly enhanced the cell viability inhibition in the presence of increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 μM) in T98G and U87 glioblastoma cancer cells (Figure 1C and D). These findings suggested that overexpression of miR-152-3p would enhance cytotoxicity of cisplatin in glioblastoma.

Inhibition Of miR-152-3p Decreased Cisplatin Sensitivity In Glioblastoma
Transfection of miR-152-3p inhibitor significantly decreased miR-152-3p levels in two cell lines (Figure 2A). Similarly, decreased expression of miR-152-3p did not influence cell viability of T98G and U87 cells (Figure 2B). In contrast to overexpression of miR-152-3p, decreased miR-152-3p observably attenuated the cytotoxicity of cisplatin (0, 2.5, 5, 10, 20, 40 μM) on cell viability in T98G and U87 cells (Figure 2C and D). These data collectively indicated that miR-152-3p could regulate cisplatin sensitivity in glioblastoma.

miR-152-3p Enhanced Cisplatin-Induced Cell Apoptosis In Glioblastoma
The cytotoxic effect of cisplatin was mainly through inducing cell apoptosis in cancer cells.10 Flow cytometry analysis was used to detect cell apoptosis upon miR-152-3p overexpression with or without cisplatin treatment in T98G cells. Results showed that both miR-152-3p overexpression and low concentration of cisplatin (5 μM) could induce cell apoptosis in T98G, and overexpression of miR-152-3p could dramatically enhance cisplatin-induced cell apoptosis (Figure 3A and B). Furthermore, similar results were observed in U87 cells (Figure 3C and D). In agreement with indicated results, knockdown of miR-152-3p lessened cell apoptosis rate increased by cisplatin (Figure S1A). In conclusion, miR-152-3p could intensify cell apoptosis induced by cisplatin in glioblastoma.

miR-152-3p Heightened TMZ Sensitivity Of Glioblastoma Cells
Based on above findings, we surmised that miR-152-3p had the same effect on TMZ resistance of glioblastoma cells. CCK-8 assay demonstrated that enhanced expression of miR-152-3p overtly diminished cell viability suppressed by different concentrations of TMZ (0, 25, 50, 100, 200, 400 μM)
in T98G and U87 cells (Figure 4A). It was indicated by flow cytometry analysis that overexpression of miR-152-3p fortified cell apoptosis caused by 100 μM TMZ in glioblastoma (Figure 4B). Inversely, silencing of miR-152-3p promoted cell viability induced by TMZ and reversed cell apoptosis enhanced by TMZ (Figure 4C and D). Taken together, miR-152-3p inhibited TMZ resistance in glioblastoma.

miR-152-3p Negatively Regulated SOS1 By Binding To Its 3’-UTR

The above results indicated that miR-152-3p could enhance the anticancer effect of cisplatin, but its mechanism was still to be clarified. According to TargetScan database, SOS1 was predicted to be a potential target gene of miR-152-3p, there was a putative binding site of miR-152-3p at the SOS1 3’-UTR (Figure 5A). Overexpression of miR-152-3p dramatically restrained SOS1 mRNA and protein expression levels in T98G and U87 glioblastoma cells (Figure 5B–D). In contrast, decreased expression of miR-152-3p observably augmented SOS1 mRNA and protein expression in T98G and U87 glioblastoma cells (Figure 5E–G). We constructed WT or Mut of SOS1 3’-UTR luciferase reporter gene plasmids to verify the association between miR-152-3p and SOS1. The dual-luciferase reporter gene assay result showed that miR-152-3p mimic dramatically decreased the luciferase activity only in the SOS1 3’-UTR-WT co-transfection system in T98G (Figure 5H). The data suggested that miR-152-3p directly repressed SOS1 expression in glioblastoma cells. Moreover, cell viability had no significant alterations when SOS1 was knocked down (Figure S1B). However, we observed that the depletion of SOS1 strengthened the inhibitory effect of cisplatin on cell viability in glioblastoma (Figure S1C). Consistently, SOS1 inhibition facilitated cell apoptosis induced by cisplatin of glioblastoma cells (Figure S1D).
miR-152-3p Strengthened Cytotoxicity Of Cisplatin Via Repression Of SOS1

To further investigate whether miR-152-3p regulated cisplatin sensitivity via regulation of SOS1 expression, we constructed pcDNA3-SOS1 recombinant plasmids and co-transfected with miR-152-3p mimic into T98G cells. Results proved that protein expression level of SOS1 dramatically reduced when overexpressed miR-152-3p; however, when co-transfected miR-152-3p with pcDNA3-SOS1 recombinant plasmid, the protein expression of SOS1 recovered (Figure 6A and B). In cell viability and apoptosis assays, data showed that overexpression of miR-152-3p would augment cisplatin-induced cell viability reduction and cell apoptosis which was reversed after transfection of recombinant SOS1 (Figure 6C–E). Considering that miR-152-3p has been justified to exert its role through targeting DMNT1 in glioblastoma, we further probed the function of miR-152-3p/DMNT1 pathway in glioblastoma. Our results revealed that overexpression of DMNT1 abolished the impact of miR-152-3p upregulation on glioblastoma cell viability and apoptosis (Figure S1E–F). In conclusion, miR-152-3p regulated cisplatin sensitivity through repression of SOS1/DMNT1 expression in glioblastoma.

miR-152-3p Levels Negatively Correlated With SOS1 mRNA Expression In Glioblastoma Tumor Tissues

To explore whether regulatory association between miR-152-3p and SOS1 also exists in cancer patient samples, 40 glioblastoma tissues and paired normal samples were collected and analyzed via RT-qPCR. It was disclosed that miR-152-3p levels negatively correlate with SOS1 mRNA expression in glioblastoma tumor tissues, further supporting the role of miR-152-3p in modulating glioblastoma cell survival and resistance to chemotherapy.
that miR-152-3p was weakly expressed in tumor specimens compared with normal tissues (Figure 7A). The expression of SOS1 in glioblastoma samples was higher than that in non-tumor tissues (Figure 7B). Results revealed that SOS1 mRNA expression was negatively correlated with miR-152-3p levels (Figure 7C).

**Discussion**

Glioblastoma is a grade IV astrocytoma defined by the world health organization (WHO) which is defined as the most aggressive glioma, and is characterized by poorly differentiated neoplastic astrocytes. Although significant achievements have been made in the past, clinical
Figure 4 MiR-152-3p heightened TMZ sensitivity of glioblastoma cells. (A) The cell viability assay illustrated that miR-152-3p mimic strengthened the TMZ-induced inhibition of cell viability. (B) The role of miR-152-3p in TMZ-induced cell apoptosis was estimated by flow cytometry. (C) miR-152-3p inhibitor could remarkably elevate the viability of glioblastoma cells treated with TMZ. (D) miR-152-3p inhibitor could significantly reduce cell apoptosis percentage of glioblastoma cells treated with TMZ.

*p<0.05, **p<0.01.
Figure 5 MiR-152-3p negatively regulated SOS1 and could bind to its 3'-UTR. (A) Bioinformatics database prediction of the putative binding site of miR-152-3p on 3'-UTR of SOS1. (B) Compared to miR-NC mimic, miR-152-3p mimic significantly decreased SOS1 mRNA expression in T98G and U87 glioblastoma cells. (C) Compared to miR-NC mimic, miR-152-3p mimic significantly decreased SOS1 protein expression in T98G and U87 glioblastoma cells. (D) Analyzed data from figure C, miR-152-3p prominently reduced SOS1 protein expression in T98G and U87 glioblastoma cells. (E) In comparison to miR-NC inhibitor, miR-152-3p inhibitor observably increased SOS1 mRNA expression in T98G and U87 glioblastoma cells. (F) In comparison to miR-NC inhibitor, Western blot showed that miR-152-3p inhibitor observably increased SOS1 protein expression in T98G and U87 glioblastoma cells. (G) Analyzed data from figure F, miR-152-3p prominently increased SOS1 protein expression in T98G and U87 glioblastoma cells. (H) Luciferase activity was significantly decreased when co-transfected with miR-152-3p mimic and SOS1 3’UTR-WT reporter plasmid in T98G. However, luciferase activity was unaltered when co-transfected with miR-152-3p mimic and SOS1 3’UTR-Mut reporter plasmid. **p<0.01, ***p<0.001.
Figure 6 Overexpression of miR-152-3p augmented cisplatin’s anti-tumor effect via repression of SOS1. (A) Compared to miR-NC mimic, miR-152-3p mimic dramatically decreased SOS1 protein expression, while SOS1 overexpression could reverse the downregulated SOS1 expression. (B) Analyzed data from figure A, in comparison to miR-NC mimic, miR-152-3p mimic notably reduced SOS1 protein expression, but additional SOS1 could reverse the downregulated SOS1 expression. (C) Compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid significantly weaken cell viability with increasing concentration of cisplatin (0, 2.5, 5, 10, 20, 40 μM), co-transfection of recombinant SOS1 plasmid and miR-152-3p reversed miR-152-3p mimic-induced decline of cell viability in T98G cells. (D) Compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid significantly enhanced cisplatin (5 μM) induced cell apoptosis, but transfection of recombinant SOS1 plasmid reversed miR-152-3p mimic-induced augment of cell apoptosis in T98G cells. (E) Analyzed data from figure D, compared to control group, miR-152-3p mimic co-transfected with pcDNA3 plasmid statistical significance increased cisplatin (5 μM) induced cell apoptosis, but transfection of recombinant SOS1 plasmid statistical significance reversed miR-152-3p mimic-induced augment of cell apoptosis in T98G cells. *p<0.05, **p<0.01, ***p<0.001.
treatment of patients with glioblastoma remains a major challenge.\textsuperscript{31} As is known to all, chemotherapy resistance is a major problem in glioblastoma treatment.\textsuperscript{32} Jia et al have found that miR-7-5p could enhance temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.\textsuperscript{33} Zeng et al have reported that exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.\textsuperscript{34} Up to now, only several studies explored the role of miRNAs in cisplatin resistance of glioblastoma.\textsuperscript{35,36} Li et al have explored that miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma.\textsuperscript{35} Yang et al have discovered that miR-29a overexpression improves sensitivity of cisplatin in CD133\textsuperscript{+} glioblastoma cells (T98G and U87MG) and significantly suppresses tumor growth in CD133\textsuperscript{+} glioblastoma tumor-bearing mice in response to cisplatin treatment.\textsuperscript{36} In this research, we creatively explored the function of miR-152-3p in cisplatin sensitivity of glioblastoma, and found that miR-152-3p could increase cisplatin-induced cytotoxicity in U87 and T98G glioblastoma cells.

Since the discovery of miR-152-3p, it has been considered as a tumor suppressor in multiple solid tumors and has been shown to be abnormally down-regulated in glioblastoma.\textsuperscript{14,37} Previous studies have shown that, miR-152-3p overexpression prevents tumor cell growth in endometrial cancer,\textsuperscript{38} miR-152-3p suppressed cell proliferation, migration, colony formation and invasion in non-small cell lung cancer,\textsuperscript{39} and miR-152-3p inhibited glioblastoma cell invasion and proliferation activities via decreasing DNA

Figure 7 MiR-152-3p expression negatively correlated with SOS1 mRNA expression in glioblastoma tissues. (A, B) RT-qPCR analysis was applied to explore the expression of miR-152-3p and SOS1 in clinical samples. (C) Pearson correlation analysis showed that SOS1 mRNA expression levels were negatively correlated with miR-152-3p expression levels in tumor tissues from 40 patients with glioblastoma ($r = -0.687$), *$p<0.01$.\textsuperscript{36}
Methyltransferase 1 (DNMT1) and the restoration of miR-152-3p had therapeutic significance in glioblastoma treatment. Additionally, miR-152-3p contributed to ovarian cancer cisplatin resistance through direct target DNMT1. In this research, according to TargetScan database prediction, we found that miR-152-3p could negatively regulate SOS1 and influence glioblastoma cisplatin sensitivity. SOS1 is known to be overexpressed in various cancers and plays an important role in many cascade signaling pathways. Lv et al have reported that miR-124 could regulate SOS1 to affect glioblastoma growth. Our study innovatively explored the regulatory effect of miR-152-3p on SOS1 in glioblastoma, and our results suggested that SOS1 inhibited the sensitivity of glioblastoma cells to cisplatin and miR-152-3p executed its function in cisplatin resistance of glioblastoma cells via targeting SOS1.

In conclusion, our research demonstrated that miR-152-3p negatively regulated SOS1 to increase cytotoxicity of cisplatin in glioblastoma. Our findings provided new insights on the targeted delivery of miR-152-3p to glioblastoma cells as a potential therapeutic treatment for glioblastoma.

Acknowledgements
This work is supported by Medical Scientific Program of Shanghai Health and Family Planning Commission (201540163), Scientific Program of Jiangsu Province (BE2018643), Scientific Program of Changzhou (CJ20180029; CE20175025), 333 Projects of Jiangsu Scientific Research Program (BRA2018168), and Scientific Program of Shandong Provincial Department of Education (J18KA254).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Jakubowicz-Gil J, Langner E, Wertel I, Piersiak T, Rzeski W. Temozolomide, quercetin and cell death in the MOGCCCM astrocytoma cell line. Chem Biol Interact. 2010;188(1):190–203. doi:10.1016/j.cbi.2010.07.015
2. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123. doi:10.1056/NEJM200101113440207
3. Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–1542. doi:10.1016/j.ejca.2011.12.013
4. Grobben B, Dyen PD, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310(3):257–270. doi:10.1007/s00441-002-0651-7
5. Yang H, Qiong-Ni Z, Jun-Li D, et al. Emerging role of long non-coding RNAs in cisplatin resistance. Onco Targets Ther. 2018;11:3185–3194. doi:10.2147/OTT.S151804
6. Parra E, Gutiérrez L, Ferreira J. Inhibition of basal JNK activity by small interfering RNAs enhances cisplatin sensitivity and decreases DNA repair in T98G glioblastoma cells. Oncol Rep. 2015;33(1):413–418. doi:10.3892/or.2014.3570
7. Liu X, Sun K, Wang H, et al. Knockdown of retinoblastoma protein may sensitize glioma cells to cisplatin through inhibition of autophagy. Neurosci Lett. 2016;620:137–142. doi:10.1016/j.neulet.2016.04.001
8. Roberts NB, Wadajkar AS, Winkles JA, Davila E, Kim AJ, Woodworth GF. Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma. Oncoinmunology. 2016;19:5–9.
9. Gajski G, Chimbor-Kovko T, Rak S, Osmak M, Garaj-Vrhovac V. Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin. Cytotechnology. 2016;68(4):1197–1205. doi:10.1007/s10616-015-9879-4
10. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–1883. doi:10.1038/onc.2011.384
11. Qian Z, Zhou S, Zhou Z, et al. MiR-146b-5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. Oncol Rep. 2017;38:2941–2950. doi:10.3892/onc.2017.9570
12. Wong STS, Zhang X, Zhuang JT, et al. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Anticancer Res. 2012;32(7):2835–2841.
13. Bai Y, Liao H, Liu T, et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer. 2013;49(3):710–724. doi:10.1016/j.ejca.2012.08.020
14. Sun J, Tian X, Zhang J, et al. Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2. MiR-152-3p regulates glioma cell apoptosis and invasion. J Exp Clin Cancer Res. 2017;36(1):100–113. doi:10.1186/s13046-017-0567-4
15. Garofalo M, Croce CM. microRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011;51(1):25–43. doi:10.1146/annurev-pharmtox-010510-100517
16. Ramalho-Carvalho J, Fromm B, Henrique R, Jeronimo C. Deciphering the function of non-coding RNAs in prostate cancer. Cancer Metastasis Rev. 2016;35(2):235–262. doi:10.1007/s10555-016-9628-y
17. Adams BD, Kasimki AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Annu Rev Pharmacol Toxicol. 2011;51(1):25–43. doi:10.1146/annurev-pharmtox-010510-100517
18. Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2007;302(1):1–12.
19. Ma J, Yao Y, Wang P, et al. MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4. Cancer Lett. 2014;355(1):85–95. doi:10.1016/j.canlet.2014.09.012
20. Azizi M, Teimoori-Toolabi L, Arzanani MK, et al. MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther. 2014;15(4):419–427. doi:10.4161/cbt.27630
21. Gureasko J, Galush WJ, Boykevisch S, et al. Membrane-dependent signal integration by the Ras activator Son of sevenless. Mol Biol Cell. 2008;19:5–12.
22. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Son. Nat Cell Biol. 2007;9(6):706–712. doi:10.1038/ncb1594
23. Pierre S, A S B, Couroul X. Understanding SOS (Son of Sevenless). Biochem Pharmacol. 2011;82(9):1049–1056. doi:10.1016/j.bcp.2011.07.072
24. Lv Z, Yang L. miR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep. 2013;8(2):345–349. doi:10.3892/mmr.2013.1561
25. Margarit SM, Sondermann H, Hall BE, et al. Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell. 2003;112(5):685–695. doi:10.1016/s0092-8674(03)00149-1
26. Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294(5545):1299–1304. doi:10.1126/science.1060203
27. Liu X, Song B, Li S, Wang N, Yang H. Identification and functional analysis of the risk microRNAs associated with cerebral low-grade glioma prognosis. Mol Med Rep. 2017;16:1173–1179. doi:10.3892/mmr.2017.6705
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi:10.1006/meth.2001.1262
29. Ge S, Wang D, Kong Q, Gao W, Sun J. Function of miR-152 as a tumor suppressor in human breast cancer by targeting PIK3CA. Oncol Res Featuring Preclin & Clin Cancer Ther. 2017;25(8):1363–1371. doi:10.3727/096504017X14878536973557
30. Trejo-Solis C, Serrano-Garcia N, Escamilla-Ramírez Á, et al. Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma. Int J Mol Sci. 2018;19(3):644–653. doi:10.3390/ijms19123773
31. Staberg M, Michaelsen SR, Rasmussen RD, et al. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol. 2017;40(1):21–32. doi:10.1007/s13402-016-0301-9
32. Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today. 2015;20(7):899–905.
33. Jia B, Liu W, Gu J, et al. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Exp Cell Res. 2018;354(9):386–396.
34. Zeng A, Wei Z, Yan W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Cancer Lett. 2018;396:10–21. doi:10.1016/j.clet.2018.08.004
35. Li J, Song J, Guo F. miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Int J Mol Med. 2019;43:517–524. doi:10.3892/ijmm.2018.3940
36. Yang L, Li N, Yan Z, Li C, Zhao Z. MiR-29a-mediated CD133 expression contributes to cisplatin resistance in CD133+ glioblastoma stem cells. J Mol Neurosci. 2018;66(3):369–377. doi:10.1007/s12031-018-1177-0
37. You W, Zhang X, Ji M, et al. MiR-152-5p as a tumor suppressor strand special functions in human gastric cancer cells. Int J Biol Sci. 2018;14(6):644–653. doi:10.7150/ijbs.25272
38. Tsuruta T, Kozaki K, Uesugi A, et al. MiR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011;71(20):6450–6462. doi:10.1158/0008-5472.CAN-11-0364
39. Su Y, Wang Y, Zhou H, Lei L, Xu L. MicroRNA-152 targets ADAM17 to suppress NSCLC progression. FEBs Lett. 2014;588(10):1983–1988. doi:10.1016/j.febslet.2014.04.022
40. Xiang Y, Ma N, Wang D, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly. A novel epigenetic therapy independent of decitabine. Oncogene. 2014;33(3):378–386.
41. Dritschilo. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol. 2009;35(4):751–760.